Delivery Order SPE2DB22D9353-SPE2DB25FX2CV
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $148,084.30 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 3,750 units of Asparlas 5 milliliter vials. This firm fixed-price delivery order is expected to reach completion by August 29, 2025, and represents a continuation of the companies' ongoing pharmaceutical supply relationship. The award carries no set-aside designation, indicating that DMS...
- The Defense Logistics Agency awarded a firm fixed-price delivery order to DMS Pharmaceutical Group Inc. on July 31, 2025, with a ceiling value of $29,616.86 for the supply of 3,750 units of Asparlas 5 ML vials. Asparlas is a leukemia treatment medication, and this delivery order will be fulfilled from DMS Pharmaceutical Group's existing Indefinite Delivery Contract with DLA under the SPE2DB program, a comprehensive pharmaceutical supply agreement valued at $499,999,999 and valid through November...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $52,599.60, is for the delivery of 3,750 units of the pharmaceutical product Asparlas (5 ml vial) by September 14, 2023. DMS Pharmaceutical Group holds a large Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $27,614.78 fixed-price contract is for the delivery of 3,750 units of the drug Asparlas (5 mL vials) with a performance period through May 13, 2024. The award is issued under DMS Pharmaceutical Group's $499,999,999 single-award indefinite delivery contract (IDC) with the DLA, which allows the agency to...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $26,299.79 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of 3,750 units of the 5 ML vial of the pharmaceutical drug Asparlas. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program....
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $27,614.78, is for the delivery of 3,750 units of the drug ASPARLAS (5 mL vials) with a completion date of May 17, 2024. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which runs through...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $110,459.16 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the supply of 3,750 units of the 5 ML ASPARLAS (asparaginase erwinia chrysanthemi) vial to support the medical needs of military healthcare facilities. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with...
- This firm fixed-price delivery order, valued at $248,533.02, was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, which has a completion date of May 6, 2024, is for the delivery of 3,750 units of the oncology drug ASPARLAS in 5 mL vials. DMS Pharmaceutical Group Inc. holds a significant indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999,...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $29,616.86 delivery order is for the supply of 3,750 units of the 5 mL vial of the drug ASPARLAS, with a performance period ending on June 4, 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the provision of 3,750 units of the drug ASPARLAS (5 ML vial) with a ceiling value of $82,844.34. This delivery order is part of DMS Pharmaceutical Group's larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which allows the DLA to issue delivery orders...
- SPE2DB22D9353Indefinite Delivery Contract
- SPE2DB22D9353-SPE2DB25FX2CVDelivery Order
On August 21, 2025, the Defense Logistics Agency awarded a firm fixed-price delivery order valued at $59,233.74 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The delivery order calls for 3,750 units of Asparlas (5 mL vials) to be delivered by September 12, 2025. This award carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on an unrestricted basis. Asparlas is a pediatric acute lymphoblastic leukemia treatment, reflecting the Defense Logistics Agency's ongoing procurement of specialty oncology and pharmaceutical products to support military healthcare facilities. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency valued at $499,999,999 and extending through November 2026. The parent contract, administered through the SPE2DB program, enables the agency to procure a comprehensive portfolio of pharmaceutical products including branded and generic prescription drugs, biologics, over-the-counter medications, and medical consumables. DMS Pharmaceutical Group's established position as a critical supplier within the federal pharmaceutical supply chain allows it to fulfill specialized medical product requirements across Department of Defense healthcare facilities worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $59.2k | 8/21/25 |